Source comparison
Sermorelin vs Tesamorelin
Tesamorelin is the compound with the strongest clinical evidence for peptide-driven fat loss. It is a full-length GHRH analog (44 amino acids versus sermorelin's 29) with an added trans-3-hexenoic acid group that extends its half-life to 26-38 minutes. Tesamor
This comparison does not assign a generated winner or score.
- Tesamorelin is the compound with the strongest clinical evidence for peptide-driven fat loss. It is a full-length GHRH analog (44 amino acids versus sermorelin's 29) with an added trans-3-hexenoic acid group that extends its half-life to 26-38 minutes.
- Tesamorelin received FDA approval in 2010 for reducing visceral adipose tissue in HIV-positive patients with lipodystrophy. In placebo-controlled trials, tesamorelin reduced trunk fat by 15-18% over 26 weeks and visceral adipose tissue by approximately 15% as measured by CT scan (Falutz et al., 2007). This is the strongest clinical evidence any GHRH analog has for targeted visceral fat reduction.
- Sermorelin is less potent per milligram and has a shorter half-life, but it is substantially cheaper and more widely available through compounding pharmacies. Users who want the most evidence-backed option for visceral fat specifically should consider tesamorelin. Those who want a cost-effective GH restoration approach with good overall body composition benefits will find sermorelin sufficient.